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Abstract
 
T cell–specific adapter (TSAd) protein is an Src homology 2 (SH2) domain–containing adapter
molecule implicated in T cell receptor for antigen (TCR)-mediated interleukin 2 (IL-2) secre-
tion in T cells. Here, we demonstrate that a substantial fraction of TSAd is found in the T cell
nucleus. Nuclear import of TSAd is an active process that depends on TSAd SH2 domain rec-
ognition of a phosphotyrosine-containing ligand. Importantly, we show that TSAd can act as a
potent transcriptional activator in T cells. Furthermore, the TSAd SH2 domain appears to be
essential for this transcription-activating function independent of its role in nuclear import.
Biochemical analyses suggest that a single TSAd SH2 domain ligand of 95–100 kD may be in-
volved in these processes. Consistent with a role as a transcription activator, cotransfection of
TSAd with an IL-2 promoter–reporter gene construct results in a considerable upregulation of
IL-2 promoter activity. Further, we show that this augmentation requires a functional TSAd
SH2 domain. However, TSAd does not appear to modulate the activity of the major recog-
nized IL-2 gene transcription factors, nuclear factor 
 
 
 
B (NF-
 
 
 
B), nuclear factor of activated T
cells (NFAT), or activator protein 1 (AP-1). These findings point to the function of TSAd as a
novel transcription-regulatory protein in T cells and illustrate the importance of the TSAd SH2
domain in this role.
Key words: transcription • T lymphocyte • interleukin 2 • signal transduction • SH2 domain
 
Introduction
 
Adapter proteins play important roles in mammalian cell
signaling through the formation of intracellular signaling
complexes with catalytically active molecules (1). In human
T cells, one such adapter protein is the T cell–specific
adapter (TSAd) protein, whose expression is induced by
TCR cross-linking (2, 3). TSAd comprises of an NH
 
2
 
-ter-
minal region of unknown function, a centrally located Src
homology 2 (SH2) domain with the potential to bind
phosphotyrosine-containing protein ligands, and a COOH-
terminal region which contains both a proline-rich stretch
and tyrosine residues which, if phosphorylated, could func-
tion as docking sites for other signaling proteins.
The murine ortholog of TSAd is known as LCK-associ-
ated adapter protein (LAD) or RLK/ITK-binding protein
(RIBP), based on its ability to interact with these respective
Src and Tec family kinases, at least in yeast hybrid systems
(4, 5). Like TSAd, LAD/RIBP is restricted in expression to
T cells and is induced upon TCR engagement. The func-
tion of TSAd and LAD/RIBP in T cells is unknown. Con-
stitutive expression of TSAd in human Jurkat T leukemic
cell line stable transfectants was previously shown to result
in inhibition of TCR plus phorbol ester–induced activa-
tion of the promoter for the T cell autocrine growth factor,
IL-2. In addition, TSAd was shown to inhibit the tyrosine
kinase activity of LCK when both were transfected into a
fibroblast cell line (3). These findings, therefore, suggested
that TSAd might function as a negative feedback regulator
of T cell activation. However, in stark contrast to this, T
cells from LAD/RIBP knockout mice were demonstrated
to produce considerably reduced quantities of IL-2 and
IFN-
 
  
 
upon TCR challenge, compared with control T
cells (5). This finding indicates that TSAd/LAD/RIBP in
fact performs a net positive role in T cell signal transduc-
tion, in induction of Th1-type T cell cytokines.
In these studies we show that TSAd has a predominant
nuclear localization in T cells and can function as a potent
activator of gene transcription in in vivo transactivation as-
says. Both TSAd nuclear import and transcription-activat-
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ing function appear to be mediated by TSAd SH2 domain
recognition of a phosphotyrosine-containing ligand. We
confirm that, under certain conditions in T cell transient
transfection assays, TSAd can indeed activate gene tran-
scription from an IL-2 promoter–reporter gene construct
and that this activation requires an intact TSAd SH2 do-
main. These findings illustrate the function of TSAd as a
potential transcription-regulatory protein in T cells.
 
Materials and Methods
 
TSAd DNA Constructs.
 
DNA corresponding to the TSAd
full-length coding region or SH2 domain only was generated by
PCR and inserted into the multiple cloning sites of pEF-FLAG
(6), pSG424 (7), or pGEX3X (Amersham Pharmacia Biotech).
Resulting constructs encode for NH
 
2
 
-terminal FLAG, GAL4
DNA-binding domain (dbd) (1–147), and glutathione 
 
S
 
-trans-
ferase (GST)-tagged TSAd proteins, respectively. Arginine to
lysine 120 (R120K) mutations of the TSAd SH2 domain were
made with the use of a QuickChange site-directed mutagenesis
kit (Stratagene).
 
Intracellular Staining.
 
Jurkat Tag C15 human T leukemia cells
(8), COS-7 African Green Monkey kidney fibroblast–like cells
(American Type Culture Collection), and 293T human kidney
epithelial cells were transfected with pEF-FLAG or pSG424 con-
structs by electroporation (250 V, 960 
 
 
 
F, 0.4-cm gap cuvettes).
After 24 h, cells were cytospun, and fixed and permeabilized in
3.75% formaldehyde/0.1% Triton X-100, and stained with anti-
FLAG M2 (Sigma-Aldrich) or anti-GAL4 (Santa Cruz Bio-
technology, Inc.) antibodies followed by goat anti–mouse Ig
(GAM)-Alexa 488 or Texas red-X (Molecular Probes). To detect
endogenous TSAd, regular Jurkat cells (American Type Culture
Collection) were prestimulated with PMA (1 ng/ml; Sigma-
Aldrich) plus ionomycin (1 
 
 
 
M; Sigma-Aldrich) for 24 h. Fixed
and permeabilized cells were then stained with an affinity-puri-
fied monospecific anti-TSAd antibody (3) followed by goat anti–
rabbit Ig (GAR), rabbit anti–goat Ig, and GAR-Alexa 488 (Mo-
lecular Probes). In all experiments, cells were counter-stained
with Hoechst 33342 (Sigma-Aldrich) or TO-PRO-3 (Molecular
Probes) to reveal nuclei. Cells were viewed on a Nikon Eclipse
E600 or ZEISS LSM510 laser scanning confocal microscope.
 
Reporter Assays.
 
For GAL4 transcription transactivation as-
says, EL-4 murine thymoma cells (American Type Culture Col-
lection) and regular Jurkat cells (American Type Culture Collec-
tion) were transfected with pSG424 constructs, the pG4M2
GAL4 operator-luciferase reporter (9) and control pRL-TK re-
nilla-luciferase reporter (Promega) by lipofection using lipofect
AMINE-2000 (Life Technologies) and X-tremeGENE Q2 trans-
fection reagent (Roche), respectively. After 6 h, EL-4 cells were
stimulated with the 145-2C11 mAb (CD3 component of the
TCR complex, 1 
 
 
 
g/ml; BD PharMingen) or PMA (50 ng/ml)
and Jurkat cells with PMA (1 ng/ml) plus ionomycin (1 
 
 
 
M) for
a further 24 h. Luciferase activity in cell lysates was measured with
the use of a Dual-Luciferase Reporter Assay System (Promega).
For other promoter assays, Jurkat cells were transfected with
pEF-FLAG constructs, together with a 
 
 
 
326 to 
 
 
 
46 IL-2 pro-
moter-luciferase reporter (10), a nuclear factor 
 
 
 
B (NF-
 
 
 
B)-
luciferase reporter (Stratagene), or nuclear factor of activated T
cells (NFAT)/activator protein 1 (AP-1)-luciferase reporter (11)
and control pRL-TK by lipofection as above. After 24 h, cells
were stimulated for a further 12–14 h with different combinations
of OKT3 mAb (CD3, 1 
 
 
 
g/ml; American Type Culture Collec-
tion) plus CD28.2 mAb (CD28, 1 
 
 
 
g/ml; BD PharMingen),
PMA (1 ng/ml), and ionomycin (1 
 
 
 
M). Luciferase activity was
measured as above.
 
GST Pulldown Assays.
 
GST fusion proteins were produced in
protease-negative BL21(DE3)pLysS(Ion,ompT
 
 
 
) bacteria (No-
vagen) and purified on glutathione-agarose beads. Jurkat cells
were preactivated with PMA (1 ng/ml) plus ionomycin (1 
 
 
 
M)
for 48 h followed by pervanadate treatment (0.5 mM) for 20 min.
Aliquots of beads, coated with 400 ng of protein, were rotated for
2 h in a 1-ml volume with NP-40 lysates or with cytoplasmic or
nuclear lysates of Jurkat (12) prepared from 
 
 
 
4 
 
 
 
 10
 
7
 
 cells. Beads
were washed extensively, and proteins were eluted in reducing
SDS sample buffer and run on 10% polyacrylamide gels. Tyrosine
phosphorylated proteins were detected by Western blotting using
the RC20 antiphosphotyrosine antibody (Transduction Labora-
tories) as described (13). The quality of nuclear and cytoplasmic
lysates was determined by stripping and reprobing of blots with
antiinhibitor 
 
  
 
(I
 
 
 
B-
 
 
 
) and anti-poly ADP-ribose polymerase
(PARP) antibodies (Santa Cruz Biotechnology, Inc.).
 
Results and Discussion
 
The subcellular distribution of TSAd has not previously
been examined in detail. One recent study, which looked
at the expression of retroviral-transduced LAD/RIBP in
the murine D10 T hybridoma, suggested a predominant
cytoplasmic localization for this molecule. However, LAD/
RIBP was clearly also expressed in the nucleus of this cell
line (14). During the course of our own experiments, de-
signed to examine the function of TSAd in T cell signal
transduction, we examined the subcellular localization of
transfected FLAG-tagged TSAd in the human Jurkat T leu-
kemia cell line. Surprisingly, and in contrast to the previ-
ously reported results, we found that although TSAd was
present in the cytoplasm, the majority of transfected TSAd
was in fact nuclear localized (Fig. 1 A). Likewise, in trans-
fected COS-7 fibroblast-like cells and 293T epithelial cells
(where nuclear and cytoplasmic compartments can be more
easily discerned), TSAd was found predominantly in the
nucleus (Figs. 1 A and 2). Confocal microscopic studies of
293T transfectants confirmed that TSAd did not just simply
overlie nuclei but was present throughout the nuclear body
(excluding nucleoli; Fig. 2). The same results were also ob-
tained using green fluorescent protein–tagged TSAd and
LAD/RIBP and in live as well as fixed cells (not shown).
Consistently, nuclear localization was observed in 
 
 
 
90% of
transfected cells. In a minority of cells, TSAd was found
mostly in the cytoplasm. However, this type of distribution
was generally seen in cells that express very high levels of
transfected protein. Most importantly, with the use of
an anti-TSAd antibody we determined that endogenous
TSAd, expressed in Jurkat cells activated with PMA plus
ionomycin (Fig. 1 B) or CD3 plus CD28 mAb (not
shown), was predominantly nuclear in all cells.
We next investigated the molecular mechanism of TSAd
nuclear import. As TSAd does not contain any obvious nu-
clear localization sequence (NLS; reference 15), we instead
asked if the TSAd SH2 domain was involved. To deter-
mine if a functional SH2 domain is required for TSAD nu- 
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clear import, we examined the subcellular distribution of a
TSAd mutant in which arginine residue 120 of the SH2
domain was mutated to a lysine (R120K). Arginine residue
120, which is conserved in all SH2 domains, is predicted to
contact the phosphate group of phosphotyrosine in SH2
domain protein ligands (16). Substitution of a lysine at this
position would be expected to prevent ligand recognition.
In contrast to wild-type TSAd, TSAd (R120K) was re-
stricted to the cytoplasm of Jurkat, COS-7, and 293T cells
(Figs. 1 C and 2; TSAd was confined to the cytoplasm in
essentially all transfected cells). This finding, therefore, in-
dicates that a functional SH2 domain is necessary for nu-
clear localization of TSAd.
A requirement for the TSAd SH2 domain in nuclear im-
port of TSAd could be explained on the basis that either:
(a) nuclear import of TSAd is directly mediated by a ty-
rosine phosphorylated ligand of the SH2 domain, or (b)
that a functional SH2 domain is necessary to allow for any
posttranslational modifications of the TSAd amino and/or
carboxyl regions which constitute the import signal (either
because they expose a cryptic NLS or lead to the release of
TSAd from the constraints of an otherwise cytoplasmic re-
tention protein). To distinguish between these possibilities,
we examined the subcellular distribution of the isolated
TSAd SH2 domain that was deleted of flanking amino and
carboxyl sequences. As shown in Fig. 1 D, the isolated
TSAd SH2 domain was essentially completely nuclear in
Jurkat. In contrast, an isolated SH2 domain with an R120K
mutation was excluded from the nucleus and found only in
cytoplasm. These results argue strongly in favor of the no-
tion that a tyrosine-phosphorylated ligand of the TSAd
SH2 domain directly mediates import of TSAd into the
nucleus. Given these results, therefore, it is conceivable that
a lesser extent of nuclear localization of LAD/RIBP in the
D10 T hybridoma may reflect a lower level expression of
this ligand and/or its degree of tyrosine phosphorylation in
this cell line. Moreover, in overexpression systems, the
availability of the ligand may be limiting such that above a
certain level of expression, TSAd/LAD/RIBP accumulates
in the cytoplasm. Indeed, this would be consistent with our
observation of a correlation between expression level of
transfected protein and cytoplasmic localization.
As TSAd was found in the nucleus, we next asked if
TSAd possessed transcription-activating ability. To exam-
ine this, we produced a GAL4(dbd)–TSAd hybrid that was
transfected into EL-4 thymoma cells or Jurkat cells along
with a GAL4 operator-luciferase reporter. As shown in Fig.
3, A and B, GAL4(dbd)–TSAd behaved as a potent tran-
scription activator compared with GAL4(dbd) alone. In
EL-4 cells, this transcription-activating ability was seen
even in the absence of cellular stimulation, although it was
accentuated if, after transfection, cells were stimulated with
CD3 mAb or PMA. In Jurkat cells, constitutive TSAd
transcriptional activity was less apparent. However, after
stimulation of cells with agents such as PMA plus ionomy-
cin, TSAd transcriptional activity was readily observed. In-
Figure 1. Subcellular distribution of
TSAd. Jurkat T leukemia cells or COS-7
cells were transiently transfected with
plasmids encoding FLAG-tagged wild-
type TSAd (A), a TSAd (R120K) mutant
(C), or the TSAd SH2 domain only with
or without the R120K mutation (D). Al-
ternatively, Jurkat cells were not trans-
fected but were stimulated for 24 h with
PMA and ionomycin to induce endoge-
nous TSAd expression (B). The location
of TSAd was determined by immu-
nostaining using an anti-FLAG antibody
(A, C, and D) or an affinity-purified
monospecific anti-TSAd antibody (B;
shown in red or green). The position of
nuclei was determined by Hoescht stain-
ing (blue color). In C, the subcellular dis-
tribution of wild-type TSAd in Jurkat
is shown for comparison with TSAd
(R120K) using the same imaging method. 
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terestingly, in both T cell lines, the TSAd (R120K) mutant
displayed much reduced transcriptional activity in this as-
say. This, despite the fact that the GAL4(dbd)–TSAd
(R120K) fusion protein was found to be strongly nuclear in
transfected cells (Fig. 3 C, compare with Figs. 1 and 2),
presumably because of the presence of a strong NLS con-
tained within the GAL4(dbd) component. These findings,
therefore, reveal, (a) an additional role for the TSAd SH2
domain in transcription activation distinct from its role in
nuclear import, and (b) that TSAd transcription activation
is indirect and mediated by a TSAd SH2 domain ligand.
So as to characterize ligands of the TSAd SH2 domain
that may be involved in nuclear import and/or transcrip-
tion activation, we performed GST pulldown assays with
the use of a GST–TSAd SH2 domain fusion protein. Fig. 4
A shows that the TSAd SH2 domain bound several tyrosine
phosphorylated proteins present in NP-40 lysates of per-
vanadate-stimulated Jurkat cells. Each of these proteins rep-
resent phosphotyrosine-dependent ligands of the SH2
domain, as none were detected in pulldowns using a GST–
TSAd SH2 (R120K) fusion protein. The most prominent
tyrosine-phosphorylated species were 
 
 
 
57 and 95–100 kD.
Other species were also identified but less consistently. Spe-
cifically, Src family kinases (including LCK) and Tec family
kinases (including ITK and the human ortholog of RLK
known as TXK) were not identified as binding partners of
the TSAd SH2 domain in these experiments (not shown).
One feature that might be predicted of a TSAd SH2 do-
main nuclear import and transcription-activating ligand is,
at the least, a part presence in the nucleus. To examine this,
therefore, we performed the same GST pulldown experi-
ments only using Jurkat lysates that had been fractionated
into cytoplasmic and nuclear components. As shown in
Fig. 4 B, the 57-kD ligand was detected only in the cyto-
plasm. In contrast, the 95–100-kD ligand was found in
both the cytoplasm and nucleus in approximately equal
proportion. Within the nucleus, the 95–100-kD species
was the only ligand of the TSAd SH2 domain that was
identified. Immunoblotting of nuclear and cytoplasmic ly-
sates for I
 
 
 
B-
 
 
 
 (restricted to the cytoplasm) and PARP (re-
stricted to the nucleus) confirmed lack of contamination of
lysates by material from the opposing fraction. These re-
sults, therefore, are consistent with the notion that the 95–
100-kD species alone is involved in both TSAd nuclear im-
port and transcription activation.
Given the results from transcription assays, as well as data
generated from LAD/RIBP knockout mice, we reexam-
Figure 2. Confocal microscopic analysis of TSAd nuclear expression.
Expression of TSAd in 293T cells, transiently transfected with FLAG-
TSAd (top) or FLAG-TSAd (R120K; bottom), was examined by immu-
nostaining for the FLAG epitope (green) and confocal microscopy. Nu-
clei were revealed with the use of TO-PRO-3 (red). Serial sections, in
0.7- m increments, from the top to bottom of samples, were viewed.
Shown are select sections for each sample. The section number (in  m) is
indicated at the top of columns.
Figure 3. TSAd transcription
activation. EL-4 thymoma cells
(A) and Jurkat cells (B) were
transiently transfected with a
GAL4 operator-luciferase re-
porter and a control renilla-
luciferase reporter together with
plasmids encoding the GAL4
(dbd) alone or GAL4(dbd)–TSAd
or –TSAd (R120K) fusion pro-
teins. After 6 h, cells were acti-
vated or not (Mock) with CD3
mAb, PMA, or PMA plus iono-
mycin for a further 24 h at which
point cells were lysed and lu-
ciferase activity in cell lysates de-
termined. Results are expressed
as luminescence counts per second (LCPS). Shown are the means plus 1 SE of triplicate determinations. Data have been normalized to renilla-luciferase
counts obtained from mock stimulated samples. The same results have been obtained in at least 20 repeat experiments for EL-4 and 5 repeat experiments
for Jurkat. In C, 293T cells were transiently transfected with plasmids encoding for GAL4(dbd)–TSAd or GAL4(dbd)–TSAd (R120K). The subcellular dis-
tribution of fusion proteins was determined by immunostaining using an anti-GAL4(dbd) mAb (green). The position of nuclei was shown by Hoechst
staining (blue). 
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ined if TSAd could activate and/or enhance transcription
from an IL-2 promoter–reporter construct in Jurkat cells. A
previous study that had examined this issue used stable Jur-
kat transfectants that expressed very high levels of TSAd
(3). To address this, therefore, we examined the influence
of transiently transfected TSAd upon IL-2 promoter activ-
ity and for this purpose used regular Jurkat cells (rather than
TagC15 Jurkat cells) that express lower, more physiologic
 
levels of transfected protein. Indeed, as shown in Fig. 5 A,
transient transfection of TSAd resulted in a dramatic en-
hancement of IL-2 promoter activity in Jurkat cells that was
induced in response to different stimuli including CD3 plus
CD28 mAb, PMA plus ionomycin, and CD3 mAb plus
PMA. Generally, this influence was more pronounced at
earlier (9–14 h) rather than later (
 
 
 
24 h) time points of ac-
tivation (not shown); an effect that can presumably be ac-
Figure 5. Influence of TSAd on IL-2 promoter activity. Jurkat cells were transiently transfected with an IL-2 promoter-luciferase reporter construct
(A–C) or with NF- B or NFAT/AP-1-luciferase reporter constructs (C only), a control renilla-luciferase reporter, and constructs encoding the FLAG
epitope alone (Control) or FLAG-tagged TSAd (A–C) or FLAG-TSAd (R120K) (B only). After 24 h, cells were activated or not (Mock) with the indi-
cated stimuli for 12 h before determination of luciferase activity. Throughout, data have been normalized to renilla-luciferase counts obtained from
mock-stimulated samples and represent the means plus 1 SE of triplicate determinations. In C, the shown data are from the same experiment. The same
data shown in A, B, and C have been obtained in five, three, and four independent repeat experiments, respectively.
Figure 4. TSAd SH2 domain ligands. Glutathione
agarose beads coated with GST–TSAd SH2 domain or
–TSAd SH2 (R120K) fusion proteins were incubated
with NP-40 lysates (A) or cytoplasmic and nuclear ly-
sates (B) of PMA plus pervanadate-stimulated Jurkat
cells (cytoplasmic and nuclear lysates were derived
from the same number of cells). After extensive bead
washing, fusion protein–bound tyrosine-phosphory-
lated proteins were eluted and detected by Western
blotting using an anti-phosphotyrosine antibody (p-
Tyr). In panel A, that equivalent quantities of fusion
proteins were used in experiments was confirmed by
Coomassie blue staining of replicate SDS-page gels
(not shown). In B, blots were stripped and reprobed
with anti-I B-  and PARP antibodies (right). I B- 
was detected only in cytoplasmic lysates and PARP
only in nuclear lysates indicating relative purity of the
respective fractions. 
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counted for on the basis that, during the course of the assay,
Jurkat would be induced to express progressively increasing
quantities of their own endogenous TSAd (3). Further-
more, in the same assays, we repeatedly observed that a
TSAd (R120K) mutant was unable to augment induced IL-2
promoter activity (Fig. 5 B). This result is consistent with
the findings that a functional SH2 domain is necessary for
TSAd nuclear import and transcription activation.
The major recognized transcription factors involved in
control of IL-2 expression in T cells are NF-
 
 
 
B, NFAT,
and AP-1 (17). Therefore, we asked if the influence of
TSAd on IL-2 promoter activity was mediated through any
of these transcription factors. To examine this, TSAd was
cotransfected into Jurkat cells with an NF-
 
 
 
B reporter
(comprising of five tandem repeats of an NF-
 
 
 
B binding
site upstream of the luciferase gene) or a composite NFAT/
AP-1 reporter (comprising of three tandem repeats of an
NFAT/AP-1 binding site derived from the IL-2 promoter,
also upstream of the luciferase gene). Fig. 5 C shows that
these NF-
 
 
 
B and NFAT/AP-1–based promoters were ac-
tivated in response to CD3 plus CD28 mAb stimulation of
transfected Jurkat. However, cotransfection of TSAd failed
to augment this induced activity. In contrast, in the same
assays, TSAd did augment IL-2 promoter activity induced
by the same stimulus. Thus, these findings suggest that
TSAd may regulate IL-2 expression through communica-
tion with a distinct element of the IL-2 promoter.
In conclusion, we have identified TSAd as a potential
transcription control protein in T cells. Aside from IL-2, a
full description of which genes TSAd regulates awaits.
Whether or not TSAd directly contacts DNA has also to be
determined. As with transcription activation, contact with
DNA could be indirect. If so, then this raises the possibility
that TSAd might function as a transcription adapter protein
that mediates the formation of transcription complexes from
component DNA binding and transcription-activating parts.
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